Rock Springs Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-2,660,822
| Closed | -$100M | – | 165 |
|
|
2021
Q1 | $100M | Buy |
2,660,822
+1,939,189
| +269% | +$48.4M | 2.19% | 6 |
|
|
2020
Q4 | $12.3M | Buy |
721,633
+450,048
| +166% | +$5.64M | 0.26% | 104 |
|
|
2020
Q3 | $1.28M | Sell |
271,585
-135,144
| -33% | -$686K | 0.03% | 143 |
|
|
2020
Q2 | $2.48M | Buy |
406,729
+6,729
| +2% | +$27.7K | 0.07% | 135 |
|
|
2020
Q1 | $908K | Hold |
400,000
| – | – | 0.04% | 128 |
|
|
2019
Q4 | $1.84M | Sell |
400,000
-375,000
| -48% | -$1.49M | 0.06% | 118 |
|
|
2019
Q3 | $3M | Buy |
775,000
+248,900
| +47% | +$1.37M | 0.12% | 122 |
|
|
2019
Q2 | $3.17M | Buy |
526,100
+21,100
| +4% | +$202K | 0.11% | 121 |
|
|
2019
Q1 | $6.77M | Hold |
505,000
| – | – | 0.26% | 96 |
|
|
2018
Q4 | $4.7M | Sell |
505,000
-93,000
| -16% | -$1.11M | 0.22% | 98 |
|
|
2018
Q3 | $8.32M | Buy |
598,000
+5,000
| +0.8% | +$74.4K | 0.3% | 94 |
|
|
2018
Q2 | $9.38M | Buy |
593,000
+7,500
| +1% | +$131K | 0.36% | 88 |
|
|
2018
Q1 | $10.1M | Buy |
585,500
+160,500
| +38% | +$3.13M | 0.43% | 79 |
|
|
2017
Q4 | $9.32M | Buy |
425,000
+207,300
| +95% | +$6.67M | 0.42% | 77 |
|
|
2017
Q3 | $8.91M | Buy |
217,700
+20,700
| +11% | +$650K | 0.41% | 77 |
|
|
2017
Q2 | $5.93M | Buy |
197,000
+32,000
| +19% | +$999K | 0.3% | 91 |
|
|
2017
Q1 | $5.96M | Buy |
165,000
+1,000
| +0.6% | +$44.1K | 0.34% | 80 |
|
|
2016
Q4 | $8.22M | Sell |
164,000
-2,250
| -1% | -$118K | 0.55% | 56 |
|
|
2016
Q3 | $8.73M | Buy |
166,250
+13,250
| +9% | +$633K | 0.55% | 54 |
|
|
2016
Q2 | $6.33M | Buy |
153,000
+8,500
| +6% | +$370K | 0.47% | 67 |
|
|
2016
Q1 | $5.87M | Buy |
144,500
+9,500
| +7% | +$327K | 0.49% | 69 |
|
|
2015
Q4 | $5.6M | Buy |
135,000
+15,000
| +13% | +$503K | 0.42% | 79 |
|
|
2015
Q3 | $1.85M | Hold |
120,000
| – | – | 0.15% | 112 |
|
|
2015
Q2 | $2.98M | Sell |
120,000
-16,000
| -12% | -$356K | 0.22% | 104 |
|
|
2015
Q1 | $3.11M | Buy |
136,000
+16,000
| +13% | +$404K | 0.29% | 87 |
|
|
2014
Q4 | $3.24M | Buy |
120,000
+5,000
| +4% | +$86.1K | 0.38% | 77 |
|
|
2014
Q3 | $1.35M | Sell |
115,000
-10,000
| -8% | -$126K | 0.21% | 79 |
|
|
2014
Q2 | $1.94M | Sell |
125,000
-50,000
| -29% | -$717K | 0.35% | 71 |
|
|
2014
Q1 | $3.44M | Buy |
+175,000
| New | +$2.97M | 0.79% | 39 |
|
Rock Springs Capital Management's FPRX Position: Q2 2021 in Review
Rock Springs Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 2,660,822 shares — an estimated $100M sold.
Rock Springs Capital Management first reported a position in FPRX in Q1 2014 and held it in 29 quarters. The position peaked at $100M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Rock Springs Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Rock Springs Capital Management sold 2,660,822 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $100M.
- Rock Springs Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 29 quarters.
- Rock Springs Capital Management's Five Prime Therapeutics, Inc. position peaked at $100M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Rock Springs Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.